Innate Pharma: presentation of lung cancer data

(CercleFinance.com) - Innate Pharma announces that AstraZeneca has presented interim data from the Phase 2 NeoCOAST-2 study (NCT05061550) at the World Conference on Lung Cancer (WCLC) on September 8, 2024.


The NeoCOAST-2 randomized trial is designed to evaluate the safety and efficacy of durvalumab alone or in combination with novel agents and chemotherapy as neoadjuvant therapy in operable, early-stage non-small-cell lung cancer, followed by adjuvant treatment with durvalumab with or without these novel agents.

In this preliminary analysis of the first 60 of 72 patients in arm 2, monalizumab plus durvalumab plus platinum doublet chemotherapy achieved a pathological complete response rate of 26.7% [95% confidence interval (CI): 16.1 - 39.7] and a major pathological response rate of 53.3% [95% CI: 40.0 - 66.3].

Treatment in arm 2 showed an acceptable tolerability profile and had no impact on the surgery rate.

Dr Sonia Quaratino, Medical Director of Innate Pharma, commented: "Monalizumab is the first checkpoint inhibitor targeting the NKG2A receptor on NK and CD8 T cells. We remain very excited about the potential to extend the clinical benefit of durvalumab in the neoadjuvant and/or adjuvant phases with the addition of monalizumab for patients with non-small cell lung cancer. We look forward to the final analysis and translation of these preliminary data into patient survival data. '

Copyright (c) 2024 CercleFinance.com. All rights reserved.